AI Breaches the Barrier Towards Better CNS Drug Discovery
The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data …
From Our Partners
ArtiDock from Receptor.AI: Next-generation AI Docking That Beats DiffDock and AlphaFold-latest
Receptor.AI has announced ArtiDock, the best-in-class model for “AI docking," which predicts the binding poses of small molecule ligands in protein …
How to Discover a Preclinical Drug Candidate in Two Years
Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based …
How AI Enables Precision Oncology
Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from …
How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery
What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific …
The Power of STB CLOUD in Remote AI Drug Discovery
STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery …
The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies
Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by …
Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung
Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the …
Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®
Introduction Glioblastomas (GBM) are devastating brain tumors and rank as one of the most aggressive human cancers with a median …
Using End-to-End Wet Lab Automation Combined with Machine Learning to Industrialize Drug Discovery
Arctoris is driven by a relentless pursuit to make drug discovery better. An industry where bringing a single drug to …
Identifying High Impact Tissue Sparing E3 Ligases and Their Binders
There are many drug target classes for which unwanted on-target pharmacology limits clinical application. Understanding E3 tissue expression across both …
QUAISAR Computational Platform for Designing Targeted Protein Degraders
A key step in the targeted protein degradation (TPD) process is the formation of an induced proximity complex, where a …